Catalent Inc. Stock
-
Your prediction
Catalent Inc. Stock
Pros and Cons of Catalent Inc. in the next few years
Pros
Cons
Performance of Catalent Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalent Inc. | - | - | - | - | - | - | - |
| Opko Health Inc. | -1.970% | -0.618% | 6.107% | -2.965% | -18.949% | -55.782% | -51.401% |
| Amicus Therapeutics Inc. | 2.880% | -1.835% | -0.926% | -41.848% | -41.530% | -32.560% | -47.549% |
| Indivior plc | -1.650% | 0.000% | 22.222% | -22.930% | 1.681% | -29.855% | 234.254% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon reviewing the financials of pharmaceutical company Catalent (US symbol: ), it becomes clear that the company is experiencing growth and expansion over time. There has been a consistent increase in total assets, gross profit, and total revenues, which indicates overall improvements in their performance.
Increasing total assets: The total assets of Catalent have been on the rise, from $7.78 billion in 2020 to $9.11 billion in 2021, and then reaching $10.51 billion in 2022. This demonstrates a strong balance sheet, suggesting the company can maintain operations during periods of uncertainty or economic downturns.
Rising total revenues: The company's revenues have consistently increased from $3.09 billion in 2020 to $3.99 billion in 2021, and further to $4.83 billion in 2022. This indicates the company's sales performance and ability to generate income is on an upward trend.
